Stockwatch: Unintended consequences
This article was originally published in Scrip
Executive Summary
A recent US Supreme Court ruling allowing the continuation of a dispute between investors in the company Matrixx Initiatives and the company, could have ramifications far beyond those being debated in the case. The Matrixx position is based around its duty (or not) to disclose confidential adverse reporting events for its drug as Matrix considered the number of adverse events to be too small to be material. Matrixx investors, however,have argued that, in this case, the adverse reports were highly material. This was a view that was supported by the stock price reaction when the reports came to light (scripintelligence.com, 23 March 2011).
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.